The Adrenal Gland and Corticosteroid Therapy in Sepsis: I Certainly Remain Uncertain* A drenal dysfunction in sepsis, described for over a century and previously termed "relative adrenal insufficiency," is now labeled "critical illness-related corticosteroid insufficiency" (CIRCI) (1) . The history of the investigation, data, and practice patterns revolving around the adrenal gland and corticosteroid supplementation in septic shock is a tour de force in evidence-based uncertainty. Corticosteroid replacement in sepsis has seen an evolution in dose (high vs low), dosing strategies (bolus dosing vs infusion, taper vs no taper), duration of therapy, and guideline recommendations (2) .
High-dose steroids were commonly given until the mid-1990s when data revealed not only a lack of benefit but also harm associated with this strategy (3). On the heels of smaller studies showing earlier shock reversal and potential mortality benefit with low-dose steroids, a multicenter randomized controlled trial (RCT) showed a 10% absolute risk reduction in mortality for patients with septic shock with relative adrenal insufficiency (4). These results were not duplicated by another multicenter RCT, which differed significantly from the Annane trial (5) . Accordingly, as these data have evolved, the "official" recommendations have changed from "… are recom-mended…" (2004) to "We suggest not using…" (2012) (6, 7) .
Data suggest that CIRCI increases mortality, yet it is difficult to say who even has it, given the testing limitations to diagnose it (8) . So at least two questions still remain: 1) Does this patient have CIRCI? and 2) Should I dose this particular patient with steroids?
In this issue of Critical Care Medicine, the study by Dorin et al (9) is an attempt to tackle the first question. Using a post hoc analysis, the authors aimed to use computer-assisted modeling to examine free cortisol appearance and elimination rates (maximal cortisol secretion rate [CSR max ] and free cortisol half-life). Subjects included patients with septic shock (n = 45), patients with sepsis (n = 25), and healthy controls (n = 10) and were given a cosyntropin stimulation test within 24 hours of sepsis diagnosis. Survivors also received cosyntropin testing at hospital discharge and as outpatients. Contrary to the primary hypothesis, CSR max was higher in septic shock than in sepsis and healthy controls, and this decreased between the first and second cosyntropin tests. The free cortisol half-life was also longer in subjects with septic shock and sepsis versus controls.
The strengths of the study are its accuracy when compared to isotope dilution as well as its attempt at better refining this topic by assessing the kinetics of cortisol variables. It also has weaknesses. The small numbers and lack of patient-level details make extrapolation of these data beyond this study impossible. We do know that the original study from which these post hoc data were obtained excluded patients with hepatic and liver disease, a fact that further limits generalizability. The use of healthy subjects as a comparator group can also be debated as well. Furthermore, there was a significant age difference between the healthy controls and the patients with sepsis, raising further questions about an accurate comparator. There was also no difference in the CSR max between patients with sepsis and healthy volunteers. Given the abundance of data regarding sepsis, inflammation, and the adrenal axis, this makes little intuitive sense. Finally, although this study is an attempt at better diagnosing CIRCI, the variance in CSR max in the septic shock group shows some rather high between-subject variability. This suggests that this approach will either be inaccurate in a significant percentage of patients or needs further refinement.
What do we do with these results? Although they add to our knowledge base regarding the possible diagnosis of CIRCI, practice cannot be changed based on these data. At the end of the day, even if we can accurately diagnose CIRCI, it still does not mean that patients will benefit from exogenous steroid replacement. Anemia is easily diagnosed and associated with worse outcome in critically ill patients, yet transfusion does not improve outcome. I believe the decision to treat patients with septic shock for possible CIRCI should revolve around the question: "Is my patient more similar to the Annane trial (early septic shock with ≥ 60% mortality risk) or the CORTICUS trial?" If the former (an absolute minority of patients with sepsis), then dosing with steroids can be considered. Until our specialty is better at tailoring therapy to an individual, it will be difficult to answer these questions. In the meantime, I thank the authors of this work for advancing the science and inching us closer. D iscoveries in ICU delirium began in earnest with the publication of validated assessment tools in 2001. This spawned a number of cohort trials examining risk factors for developing delirium and the relationships between delirium and morbid events. Experts in the field warned that inherent deficiencies in trial design (unknown but important covariates) could influence outcomes and that these hypothesis-generating results needed to be confirmed with well-done prospective randomized controlled trials (RCT) (1).
Results have been inconsistent. Some foundational aspects of delirium, such as the risk factors preexisting dementia, a history of hypertension and/or alcoholism, and coma, have been consistently identified, whereas other risk factors including age and benzodiazepine use have been recently challenged (2, 3) . Delirium-associated outcomes including prolonged mechanical ventilation and ICU length of stay as well as cognitive decline have remained intact over time (4) , but the oft-stated increase in short-term mortality attributed to delirium (5) has been disputed (6) .
A planned a priori secondary analysis of the Sedation Lightening and Evaluation of A Protocol (SLEAP) trial by Mehta et al (7) published in this issue of Critical Care Medicine extends our knowledge of delirium. This investigation focused on delirium frequency, related outcomes, and risk factors using data collected during the original SLEAP trial (a multicenter, multinational RCT comparing protocolized sedation vs protocolized sedation plus daily interruption) (8) .
Mechanically ventilated patients received continuous opioid infusions with or without benzodiazepines with goals of care to maintain a "comfortable and rousable state," with wakefulness (the ability to attend to at least three commands) as the target during sedation stops. Delirium assessments were performed once daily by bedside nurses using the Intensive Care Delirium Screening Checklist (ICDSC). Importantly, the influence of sedation on ICDSC scoring was not considered, and propofolor dexmedetomidine-based sedation was not allowed.
The investigators found no difference in delirium prevalence with or without sedation interruption. Cox proportional hazards regression analysis identified physical restraints, midazolam dose (hazard ratio, 0.998/mg midazolam), and the use of antipsychotics as risk factors for developing delirium. In
